Which biotech stocks will be the next to reward risk-tolerant investors with massive returns? Today’s article highlights two small-cap contenders: a company developing “one of the most comprehensive COVID-19 platforms in the industry” (including a vaccine, a powerful neutralizing antibody and diagnostic products) and an immuno-oncology company that has surged 1,260% higher so far this year with plenty more room to run. For more on these two stocks and the potential risks and rewards associated with each, CLICK HERE.
2 Small-Cap Contenders For The Next Big Biotech Gainers
- by Alex Clarke
Tags:Biotech InvestmentsBiotech StocksGrowth PotentialGrowth StocksImmuno-oncology CompanyInvestInvestingInvestorsMassive ReturnsSmall-Cap InvestmentsStock MarketStocks